
B-cells: How do they Work and How Can We Use Them to Combat Cancer?

Edmund K. Waller, MD, PhD, FACP Emory University Disclosures for Edmund Waller (none relevant to current subject matter except *)


- Consulting to industry
 - Outsuka
 - Haplomics
- Biotech Start-up Co-founder
 - Cambium Medical Technologies (manufactured platelet lysate)
- Clinical Research Investigator
 - Sanofi
 - Outsuka
 - *CureTech

B cell Ontogeny



Copyright © 2006 Nature Publishing Group Nature Reviews | Immunology


Immunoglobulin gene rearrangements and somatic mutations create up to 10¹² different Immunoglobulin genes




Nature Reviews | Genetics

Slotkin and Martienssen Nature Reviews Genetics 8, 272-285 (April 2007)

Antibody structure and function




http://www2.ac-lyon.fr/enseigne/biologie/ress/logiciel/ana_ras/rasmol.html




Michnick & Sidhu Nature Chemical Biology 4, 326 - 329 (2008)

B-cell lymphoma expressing idiotypic determinants was an original clinical target for monoclonal Ab






Monoclonal antibodies have high affinity b. 25000



http://www.biotek.com/resources/articles/cellular-screening-therapeutic-antibodies.html

Genetically Engineered Antibodies for Humoral Cancer Immuno-therapy



Murine native (e.g. ibritum<u>omab</u>)

Chimeric (e.g. ritu<u>ximab</u>)

Humanized (e.g. trastuzumab)




Human Murine

Commercial monoclonal antibodies used to treat cancer

Rituximab	Anti-CD20	Non-Hodgkin's lymphoma 1998 (1997)
Trastuzumab	Anti-HER2	Breast cancer 2000 (1998)
Gemtuzumab ozogamicin	Anti-CD33	Acute myeloid leukemia NA (2000#)
Alemtuzumab	Anti-CD52	Chronic lymphoid leukemia 2001 (2001)
Tositumomab-I131	Anti-CD20	Non-Hodgkin lymphoma NA (2003)
Cetuximab	Anti-EGFR	Colorectal cancer 2004 (2004)
Ibritumomab tiuxetan	Anti-CD20	Non-Hodgkin's lymphoma 2004 (2002)
Bevacizumab	Anti-VEGF	Colorectal cancer 2005 (2004)
Panitumumab	Anti-EGFR	Colorectal cancer 2007 (2006)
Catumaxomab	Anti-EPCAM	Malignant ascites 2009 (NA)
Ofatumumab	Anti-CD20	Chronic lymphocytic leukemia 2010 (2009)
Ipilimumab	Anti-CTLA-4	Metastatic melanoma 2011 (2011)
Brentuximab vedotin	Anti-CD30	immunoconjugate Hodgkin 2012 (2011)
Pertuzumab	Anti-HER2	Breast Cancer 2013 (2012)
Ado-Trastuzumab emtansine	Anti-HER2	immunoconjugate Breast cancer 2013 (2013)

Rituximab-CHOP is superior to CHOP alone in older patients with diffuse large B-cell lymphoma.




Habermann TM, JCO 2006

Trastuzumab antibody to HER2 improves survival in patients with metastatic breast cancer

A 100⁵rogression-free Survival (%) 90 80 70 Chemotherapy plus trastuzumab 60 50 -40 P<0.001 30 -20 -Chemotherapy alone 10 -0 -10 0 5 15 20 25 Months after Enrollment No. AT Risk Chemotherapy 235 152 15 63 plus trastuzumab Chemotherapy alone 234 256 103


Dennis J. Slamon, , NEJM 2001

Bevacizumab added to Irinotecan, fluorouracil, and leucovorin improves survival in patients with metastatic colorectal cancer




Herbert Hurwitz, NEJM 2004

Immune cellular network mediated by tumor antigen (TA) –targeted monoclonal antibodies (mAbs) in the tumor microenvironment to induce antitumor activity.




Ferris R L et al. JCO 2010;28:4390-4399

Primary and secondary plasma cell responses




Katja Fink, Front Immunol. 2012; 3: 78.

Plasmablast




http://image.bloodline.net/stories/storyReader\$739.html

Potent plasmablast responses induced during acute dengue virus infection.




Wrammert J et al. J. Virol. 2012;86:2911-2918

The majority of the plasmablasts induced by dengue virus infection are virus specific.




High-affinity monoclonal antibodies can be generated from FACS-isolated plasmablasts



Wrammert, et al. JEM vol. 208: 181-193

Strategy to generate tumor-specific human monoclonal antibodies following cancer vaccines




Jens Wrammert, personal communication

New developments in antibody therapy


- Antibodies to check-point blockade Anti-PD1 Anti-PD-L1
- Bi-specific antibodies BiTES (bridge T cells to target)

•Expressing antibodies directly on effector cells CAR T-cells (MoAb expression on T cells) CAR NK cells (MoAb expression on NK cells)

Blinatumomab is a novel bispecific construct that reacts simultaneously to normal CD3+ T cells and CD19+ ALL cells (BiTE mechanism)



Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL



Klinger et al. Blood. 2012;120:5185-5187

What can be done to enhance the latent antitumor immune responses in patients?


Blocking inhibitory signaling to enhance latent autologous anti-tumor immunity:

Anti-CTLA-4

Anti-PDL/PDL1


Depleting T-reg

Role of blocking antibodies to CTLA4 signaling in T-cell activation and cellular immunotherapy




Cha and Fong 2011 J Clin Oncol 29:3677-3685

Ipilumumab (anti-CTLA-4) increased survival of patients with previously treated metastatic melanoma




Robert C et al. 2011. N Engl J Med 364:2517-2526.

Activity of Anti–Programmed Death 1 (PD-1) Antibody in Patients with Treatment-Refractory Melanoma, Non– Small-Cell Lung Cancer, or Renal-Cell Cancer.




Topalian et al. NEJM 2012






Activity of Anti–PD-L1 Antibody in Patients with Advanced Melanoma and Non–Small-Cell Lung Cancer.




Brahmer et al. NEJM 2012



JOURNAL of MEDICINE


Phase 2 study: Promising clinical outcomes after pidilizumab treatment following auto-transplant in NHL patients .

Pidilizumab was administered intravenously at a dose of 1.5 mg/kg every 42 days for three cycles, beginning 30 to 90 days from AHSCT.




Armand P et al. JCO 2013;31:4199-4206

Strategy of genetically-modified T-cells expressing antibodies with anti-tumor specificity



Urba WJ, Longo DL. 2011. N Engl J Med. 365:754-757.

CAR autologous T-cell immunotherapy in CLL



Porter DL et al. 2011 N Engl J Med. 365:725-733.

Conclusions

- Monoclonal antibodies to tumor-associated antigens have had a major clinical impact on improving survival in cancer patients
- New strategies to generate human MoAb to TAA may yield new targets for MoAb therapy
- Bi-specific MoAb to TAA and effector cells can be used to enhance cell-mediated immunity to cancer
- MoAb to TAA expressed directly on effector cells can augment cell-mediated immunity